{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-008267","form_type":"8-K","ticker":"MPLT","cik":"0001770069","company_name":"MapLight Therapeutics, Inc.","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.117327+00:00","generated_at":"2026-05-16T11:04:49.362988+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MapLight reports $450M cash; Phase 2 ZEPHYR & IRIS topline results now expected Q3 2026","bullets":["Preliminary cash and equivalents ~$450M as of Dec 31, 2025.","Phase 2 ZEPHYR trial for schizophrenia topline results expected Q3 2026; enrollment ahead of schedule.","Phase 2 IRIS trial for autism spectrum disorder completed enrollment; topline results also Q3 2026.","ZEPHYR is a 300-patient randomized double-blind placebo-controlled trial for acute psychosis.","IRIS trial randomized ~160 adult and adolescent participants with autism spectrum disorder."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-008267","json":"https://secwatch.observer/filing/0001193125-26-008267.json","markdown":"https://secwatch.observer/filing/0001193125-26-008267.md","text":"https://secwatch.observer/filing/0001193125-26-008267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526008267/0001193125-26-008267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770069/000119312526008267/mplt-20260109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:04:49.362988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}